Skip to main content

Effects of Coenzyme Q10 Supplementation on Serum Lipoproteins, Plasma Fibrinogen, and Blood Pressure in Patients With Hyperlipidemia and Myocardial Infarction

  • Mohseni M
  • Vafa M
  • Hajimiresmail S
  • et al.
N/ACitations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

BACKGROUND: Low plasma concentrations of coenzyme Q10 (CoQ10) have been associated with concentration of lipoproteins and other factors contributing to coronary heart diseases. OBJECTIVES: The present investigation aimed to improve the blood pressure and serum lipoproteins concentration in patients with myocardial infarction (MI) by CoQ10 supplementation. PATIENTS AND METHODS: In this randomized double-blinded controlled clinical trial, 52 Iranian patients with hyperlipidemia and MI were recruited to examine the effect of CoQ10 on serum total cholesterol (TC), LDL-C, HDL-C, triglyceride (TG), LDL-C/HDL-C ratio, TC/HDL-C ratio, fibrinogen, systolic blood pressure (SBP) and diastolic blood pressure (DBP). Individuals were randomly allocated to two groups for receiving either 200 mg/d of CoQ10 or placebo for 12 weeks. RESULTS: There were not significant differences in serum LDL-C (2.70 +/- 0.31 vs. 2.70 +/- 0.35 mmol/L), TC (4.47 +/- 0.33 vs. 4.93 +/- 0.57 mmol/L), TG (2.48 +/- 0.12 vs. 2.25 +/- 0.69 mmol/L), and fibrinogen (2.08 +/- 0.99 vs. 38.7 +/- 0.64 mg/dL) between CoQ10 and placebo groups. After 12 weeks, a significant enhancement in serum HDL-C (1.44 +/- 0.18 vs. 1.14 +/- 0.18 mmol/L) level was observed between groups after the supplementation (P < 0.001). A significant reduction of TC, LDL-C, and fibrinogen and a significant increase in HDL-C concentration was observed in CoQ10 group after intervention (P < 0.001). Our assessment demonstrated statistically significant differences between the two groups in SBP and DBP after intervention (P < 0.001). ANCOVA also revealed significant differences in the ratio of LDL-C/HDL-C and TC/HDL-C between the two groups (1.89 +/- 0.42 vs. 2.39 +/- 0.38, P = 0.002; and 3.2 +/- 0.5 vs. 4.24 +/- 0.66, P = 0.01, respectively). A significant reduction of LDL-C/HDL-C and TC/HDL-C was observed in CoQ10 group (P < 0.001). CONCLUSIONS: Twelve-week supplementation with CoQ10 in patients with hyperlipidemia and MI can improve blood pressure, serum HDL-C as well as LDL-C/HDL-C and TC/HDL-C ratios; therefore, it might decrease the risk of frequent MI.

Cite

CITATION STYLE

APA

Mohseni, M., Vafa, M. R., Hajimiresmail, S. J., Zarrati, M., Rahimi Forushani, A., Bitarafan, V., & Shidfar, F. (2014). Effects of Coenzyme Q10 Supplementation on Serum Lipoproteins, Plasma Fibrinogen, and Blood Pressure in Patients With Hyperlipidemia and Myocardial Infarction. Iranian Red Crescent Medical Journal, 16(10). https://doi.org/10.5812/ircmj.16433

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free